Anest. intenziv. Med. 2009;20(5):262-266

Regional citrate anticoagulation during continuous renal replacement therapy (CRRT) in a cardiac surgery patient with a high risk of bleeding - case reportIntesive Care Medicine - Case Report

Zuščich Ondřej*, Hájek Roman, Drobiličová Andrea
Kardiochirurgická klinika, Fakultní nemocnice Olomouc

Regional citrate anticoagulation is suitable for cardiac surgery patients with clotting abnormalities who require continuous renal replacement therapy (CRRT) in the postoperative period. Case reports point to using regional citrate anticoagulation in patients with a high risk of bleeding and document the possibility of monitoring systemic haemocoagulation during renal replacement therapy using thromboelastography. This method is used as the first option in the case of significant disturbances in blood clotting.

Keywords: regional anticoagulation; haemocoagulation; bleeding; continuous renal replacement therapy

Received: April 1, 2009; Accepted: July 31, 2009; Published: October 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zuščich O, Hájek R, Drobiličová A. Regional citrate anticoagulation during continuous renal replacement therapy (CRRT) in a cardiac surgery patient with a high risk of bleeding - case report. Anest. intenziv. Med. 2009;20(5):262-266.
Download citation

References

  1. Kroužecký, A. Antikoagulace u metod mimotělní náhrady funkce ledvin. In: Novák, I., Matějovič, M., Černý, V. et al. Akutní selhání ledvin. Praha : Maxdorf, 2008, p. 85-95.
  2. Stašek, J. Trombocytopenie jako komplikace kontinuálních očišťovacích metod. Interní medicína pro praxi, 2005, 7, 10, p. 438-439.
  3. Hájek, R., Zezula, R., Fluger, I., Růžičková, J. Význam trombelastografie pro monitorování hemostázy v kardiochirurgii. Intervenční a akutní kardiologie, 2005, 4, 4, p. 224-228.
  4. Evenepoel, P., Dejagere, T., Verhamme, P., Claes, K., Kuypers, D., Bammens, B., Vanrenterghem, Y. Heparin-coated polyacrylonitrile membrane versus regional citrate anticoagulation: a prospective randomized study of 2 anticoagulation strategies in patiens at risk of bleeding. Am. J. Kidney Dis., 2007, 49, 5, p. 642-649. Go to original source... Go to PubMed...
  5. Maňák, J., Mottl, R., Sobotka, L. Citrátová antikoagulace během kontinuální veno-venosní hemodiafiltrace - návod na provedení metody. Aktuality v nefrologii, 2006, 6, 4, p. 125-129.
  6. Cubattoli, L., Teruzzi, M., Cormio, M., Lampati, L., Pesenti, A. Citrate anticoagulation during CVVH in high risk bleeding patients. Int. J. Artif. Organs, 2007, 30, 3, p. 244-252. Go to original source... Go to PubMed...
  7. Bagshaw, S. M., Laupland, K. B., Boiteau, P. J., Godinez-Luna, T. Is regional citrate superior to systemic heparin antikoagulation for continuous renal replacement therapy? A prospective study in an adult regional critical care system. J. Crit. Care, 2005, 20, 2, p. 155-161. Go to original source... Go to PubMed...
  8. Morgera, S., Scholle, C., Voss, G., Haase, M., Vargas-Hein, O., Krausch, D., Melzer, C., Roseau, S., Zuskermann-Becker, H., Neumayer, H. H. Metabolic complications during regional citrate anticoagulation in continuous venovenous hemodialysis: single-center experience. Nephron. Clin. Pract, 2004, 97, 4, p. 131-136. Go to original source... Go to PubMed...
  9. Betjes, M. G., van Oosterom, D., van Agterem, M., van de Watering, J. Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. J. Nephrol., 2007, 20, 5, p. 602-608. Go to PubMed...
  10. Thoenen, M., Schmid, E. R., Binswanger, U., Schuepbach, R., Aerne, D., Schmidlin, D. Regional citrate anticoagulation using a citrate-based substitution solution for continuous venovenous hemofiltration in cardiac surgery patients. Wien Klin. Wochenschr., 2002, 114, 3, p. 108-114.




Anesteziologie a intenzivní medicína

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.